Alkermes Patent-Cliff Exposure & CMS Drug Spending Portfolio
Alkermes (Waltham, MA): 5 reconciled FDA prescription therapies (76.5% 2025 to 2030 cliff risk), $1.32B 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Waltham, MA |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 76.5% |
| Primary Portfolio LOE Date | 2029-01-01 |
| 2024 CMS Total Public Spend | $1.32B |
| 2024 Medicare Part D Spend | $488.6M |
| 2024 Medicaid Spend | $833.5M |
| California HCAI SB 17 Filings | 8 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.